CoChat

Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases

Open access
Brkic, Marjana, Balusu, Sriram, Libert, Claude, Vandenbroucke, Roosmarijn E. · 2015 · Mediators of Inflammation

The DOI matches its Crossref record; 307 of the 310 references it cites were found in a registry or an index.

Abstract

Neurodegeneration is a chronic progressive loss of neuronal cells leading to deterioration of central nervous system (CNS) functionality. It has been shown that neuroinflammation precedes neurodegeneration in various neurodegenerative diseases. Matrix metalloproteinases (MMPs), a protein family of zinc‐containing endopeptidases, are essential in (neuro)inflammation and might be involved in neurodegeneration. Although MMPs are indispensable for physiological development and functioning of the organism, they are often referred to as double‐edged swords due to their ability to also inflict substantial damage in various pathological conditions. MMP activity is strictly controlled, and its dysregulation leads to a variety of pathologies. Investigation of their potential use as therapeutic targets requires a better understanding of their contributions to the development of neurodegenerative diseases. Here, we review MMPs and their roles in neurodegenerative diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and multiple sclerosis (MS). We also discuss MMP inhibition as a possible therapeutic strategy to treat neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2015/620581

Cites

307 of 307 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Classification of the MMPs based on their domain organization. MMPs are grouped into four major groups: gelatinases, matrilysins, archetypal MMPs, and furin-activatable MMPs. The typical structure of MMPs consists of a signal peptide, propeptide, a catalytic domain, hinge region, and a hemopexin domain. In addition, members of the gelatinases family have extra fibronectin type II motif repeats in the catalytic domain, and matrilysins have neither a hinge region nor hemopexin domains. Furin-activatable MMPs contain a furin recognition motif and are subcategorized into either secreted or membrane bound. Based on the type of membrane attachment, they are subdivided into type I transmembrane MMPs, GPI-linked MMPs, and type II transmembrane MMPs. Type-II transmembrane MMPs lack a cysteine switch. Instead, they have a cysteine rich domain and IgG-like domain. C, C-terminal domain; FN, fibronectin; GPI, glycophosphatidylinositol; MMP, matrix metalloproteinases; N, N-terminal domain.
Figure 1 Classification of the MMPs based on their domain organization. MMPs are grouped into four major groups: gelatinases, matrilysins, archetypal MMPs, and furin-activatable MMPs. The typical structure of MMPs consists of a signal peptide, propeptide, a catalytic domain, hinge region, and a hemopexin domain. In addition, members of the gelatinases family have extra fibronectin type II motif repeats in the catalytic domain, and matrilysins have neither a hinge region nor hemopexin domains. Furin-activatable MMPs contain a furin recognition motif and are subcategorized into either secreted or membrane bound. Based on the type of membrane attachment, they are subdivided into type I transmembrane MMPs, GPI-linked MMPs, and type II transmembrane MMPs. Type-II transmembrane MMPs lack a cysteine switch. Instead, they have a cysteine rich domain and IgG-like domain. C, C-terminal domain; FN, fibronectin; GPI, glycophosphatidylinositol; MMP, matrix metalloproteinases; N, N-terminal domain.CC BY · PubMed Central
Figure 2 Schematic representation of the activation of MMPs, their interactions with cytokines and chemokines, and the outcome of the interactions. MMPs are induced and activated in the presence of an external trigger (e.g., inflammatory stimuli) or abnormal proteins (e.g., protein or peptide aggregates). The activated MMPs can alter the properties of cytokines and chemokines. They also interact with the extracellular matrix, cell surface receptors, growth factors, integrin, signaling molecules, and tight junction proteins and alter their properties. This affects neuroinflammation, cell death or survival, growth, and regeneration. ECM, extracellular matrix; MMP, matrix metalloproteinase; TJs, tight junctions.
Figure 2 Schematic representation of the activation of MMPs, their interactions with cytokines and chemokines, and the outcome of the interactions. MMPs are induced and activated in the presence of an external trigger (e.g., inflammatory stimuli) or abnormal proteins (e.g., protein or peptide aggregates). The activated MMPs can alter the properties of cytokines and chemokines. They also interact with the extracellular matrix, cell surface receptors, growth factors, integrin, signaling molecules, and tight junction proteins and alter their properties. This affects neuroinflammation, cell death or survival, growth, and regeneration. ECM, extracellular matrix; MMP, matrix metalloproteinase; TJs, tight junctions.CC BY · PubMed Central
Figure 3 Schematic representation of the involvement of MMPs in Alzheimer's disease pathology. Aβ peptides produced from APP processing form oligomers that subsequently form amyloid deposits or plaques in the brain parenchyma. Aβ oligomers activate inflammatory cells in the brain (astrocytes, microglia, and choroid plexus epithelium). Once activated, microglia change their shape, migrate close to plaques, and begin to secrete proinflammatory cytokines and MMPs. Secreted MMPs degrade Aβ and, on the other hand, exacerbate inflammation in the brain, leading to death of neurons. These cytokines and MMPs also affect the endothelial tight junctions, alter the pericyte phenotypes, and contribute to increased BBB permeability. Similarly, oligomers in the CSF activate the choroid plexus epithelium, which leads to the release of proinflammatory cytokines and MMPs. These secreted MMPs further damage the tight junctions at the BCSFB. Aβ, β-amyloid; BBB, blood-brain barrier; BCSFB, blood-cerebrospinal fluid barrier; CSF, cerebrospinal fluid; MMP, matrix metalloproteinase; TJs, tight junctions.
Figure 3 Schematic representation of the involvement of MMPs in Alzheimer's disease pathology. Aβ peptides produced from APP processing form oligomers that subsequently form amyloid deposits or plaques in the brain parenchyma. Aβ oligomers activate inflammatory cells in the brain (astrocytes, microglia, and choroid plexus epithelium). Once activated, microglia change their shape, migrate close to plaques, and begin to secrete proinflammatory cytokines and MMPs. Secreted MMPs degrade Aβ and, on the other hand, exacerbate inflammation in the brain, leading to death of neurons. These cytokines and MMPs also affect the endothelial tight junctions, alter the pericyte phenotypes, and contribute to increased BBB permeability. Similarly, oligomers in the CSF activate the choroid plexus epithelium, which leads to the release of proinflammatory cytokines and MMPs. These secreted MMPs further damage the tight junctions at the BCSFB. Aβ, β-amyloid; BBB, blood-brain barrier; BCSFB, blood-cerebrospinal fluid barrier; CSF, cerebrospinal fluid; MMP, matrix metalloproteinase; TJs, tight junctions.CC BY · PubMed Central
Figure 4 Strategies for targeting MMPs. Inflammatory triggers or protein aggregates in neurodegenerative diseases initiate an inflammatory cascade. At this early stage, various pharmacological anti-inflammatory drugs are effective in eliminating the downstream consequences. Increased inflammation induces and/or activates MMPs, and various broad spectrum inhibitors are available to inhibit MMPs. However, due to the fact that MMPs have both beneficial and detrimental effects, specific MMP inhibition might be a better approach. Finally, it is also possible to interfere at the level of the cleaved substrates, either by reconstitution of crucial substrates or by blockage or removal of effector molecules.
Figure 4 Strategies for targeting MMPs. Inflammatory triggers or protein aggregates in neurodegenerative diseases initiate an inflammatory cascade. At this early stage, various pharmacological anti-inflammatory drugs are effective in eliminating the downstream consequences. Increased inflammation induces and/or activates MMPs, and various broad spectrum inhibitors are available to inhibit MMPs. However, due to the fact that MMPs have both beneficial and detrimental effects, specific MMP inhibition might be a better approach. Finally, it is also possible to interfere at the level of the cleaved substrates, either by reconstitution of crucial substrates or by blockage or removal of effector molecules.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–307 of 307

Research works printed but not linked: 4

  1. 10.1002/(sici)1097-4547(19981001)54:160;68::aid-jnr862;3.0.co;2-f · doi:10.1002/(sici)1097-4547(19981001)54:160;68::aid-jnr862;3.0.co;2-f
  2. 10.1002/1531-8249(199912)46:660;860::aid-ana862;3.0.co;2-m · doi:10.1002/1531-8249(199912)46:660;860::aid-ana862;3.0.co;2-m
  3. Goldenberg M. M., 2012, Multiple sclerosis review, P & T, 37, 175
  4. 10.1523/JNEUROSCI.0967-12.2012 · DOI · Paper page

Cited by

See all 205

Metadata

Authors
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E.
Affiliations
Ghent University (BE)
Corresponding author
Vandenbroucke, Roosmarijn E.
Venue
Mediators of Inflammation
Publisher
Wiley
Published
2015-01
Volume
2015
Issue
1
Pages
620581-620581
ISSN
  • 0962-9351 (ISSN-L)
  • 1466-1861
OpenAlex
W2165521823
Cited by
205
References
310
Citations by year
2026: 8 · 2025: 11 · 2024: 19 · 2023: 12 · 2022: 24 · 2021: 36 · 2020: 28 · 2019: 13 · 2018: 24 · 2017: 22 · 2016: 8
FWCI
1.75
Type
journal article
Language
en
Open access
Locations
  • Mediators of Inflammation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ministry of Education, Science and Technological Development of the Republic of Serbia (ON173056)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
matrix metalloproteinases, neurodegenerative diseases, neuroinflammation, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, matrix metalloproteinase inhibition, therapeutic target
MeSH terms
Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Humans, Huntington Disease, Inflammation, Multiple Sclerosis, Parkinson Disease, Biomarkers, Gene Expression Regulation, Enzymologic, Neurodegenerative Diseases, Matrix Metalloproteinases, Neurogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.